URMC / Research / Health Research /Clinical Trials / Study Details

IMGIP22070 / CL-SBP-101-04 / Dunne

Research Question:
Does the drug, SBP-101 effectively treat metastatic pancreatic cancer?

Basic Study Information

Purpose:
The study is a randomized, double-blind, placebo-controlled, multicenter study of standard treatment with nab-paclitaxel and gemcitabine with or without SBP-101 in subjects previously untreated for metastatic pancreatic ductal adenocarcinoma (PDA), including subjects who have received prior neoadjuvant or adjuvant treatment.

Location: University of Rochester
Study Reference #: STUDY00007707

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Dunne

Study Contact Information

Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu

Additional Study Details

Contact This Study

First Name *

This field is required

Middle Name

Last Name *

This field is required

Phone Number

I agree to be contacted by The University of Rochester Medical Center regarding participation in this study. *

You must agree to be contacted to continue.

Please call me during the day.

Please call me during the evening.

Message

Return to Search

Research

UR Health Research